CardieX Toekomstige groei

Future criteriumcontroles 5/6

CardieX zal naar verwachting groeien in winst en omzet met respectievelijk 90.7% en 54.8% per jaar. De winst per aandeel zal naar verwachting groeien met 120.1% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 1% zijn.

Belangrijke informatie

90.7%

Groei van de winst

120.1%

Groei van de winst per aandeel

Medical Equipment winstgroei	16.1%
Inkomstengroei	54.8%
Toekomstig rendement op eigen vermogen	1.0%
Dekking van analisten	Low
Laatst bijgewerkt	06 Nov 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Winst- en omzetgroeiprognoses

ASX:CDX - Toekomstschattingen van analisten en financiële gegevens uit het verleden (AUD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
6/30/2027	70	40	40	40	1
6/30/2026	51	24	24	24	1
6/30/2025	17	-3	-4	-4	1
6/30/2024	13	-7	-8	-8	N/A
3/31/2024	13	-8	-7	-7	N/A
12/31/2023	14	-9	-5	-5	N/A
9/30/2023	10	-14	-9	-9	N/A
6/30/2023	6	-19	-12	-12	N/A
3/31/2023	5	-16	-11	-11	N/A
12/31/2022	4	-14	-10	-10	N/A
9/30/2022	4	-13	-10	-9	N/A
6/30/2022	5	-12	-10	-9	N/A
3/31/2022	5	-11	-9	-8	N/A
12/31/2021	5	-10	-8	-8	N/A
9/30/2021	5	-7	-6	-6	N/A
6/30/2021	6	-5	-4	-4	N/A
3/31/2021	5	-4	-3	-3	N/A
12/31/2020	5	-3	-2	-2	N/A
9/30/2020	5	-3	-2	-2	N/A
6/30/2020	5	-3	-2	-2	N/A
3/31/2020	5	-3	-2	-2	N/A
12/31/2019	5	-4	-2	-2	N/A
9/30/2019	5	-3	-2	-2	N/A
6/30/2019	5	-3	-3	-2	N/A
3/31/2019	5	-3	-3	-3	N/A
12/31/2018	4	-3	-3	-3	N/A
9/30/2018	4	-3	-2	-2	N/A
6/30/2018	4	-3	-2	-2	N/A
3/31/2018	5	-3	N/A	-2	N/A
12/31/2017	5	-4	N/A	-2	N/A
9/30/2017	5	-4	N/A	-3	N/A
6/30/2017	5	-4	N/A	-3	N/A
3/31/2017	5	-4	N/A	-4	N/A
12/31/2016	5	-4	N/A	-4	N/A
9/30/2016	5	-5	N/A	-5	N/A
6/30/2016	5	-5	N/A	-5	N/A
3/31/2016	5	-4	N/A	-4	N/A
12/31/2015	4	-4	N/A	-4	N/A
9/30/2015	5	-3	N/A	-3	N/A
6/30/2015	5	-1	N/A	-2	N/A
3/31/2015	5	-2	N/A	-2	N/A
12/31/2014	5	-2	N/A	-3	N/A
9/30/2014	5	-2	N/A	-2	N/A
6/30/2014	5	-3	N/A	-1	N/A
3/31/2014	6	-2	N/A	0	N/A
12/31/2013	6	0	N/A	1	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er wordt voorspeld dat CDX de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 2.6% ).

Winst versus markt: Er wordt verwacht dat CDX de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.

Hoge groeiwinsten: Er wordt verwacht dat CDX binnen 3 jaar winstgevend zal worden.

Omzet versus markt: De omzet van CDX ( 54.8% per jaar) zal naar verwachting sneller groeien dan de markt Australian ( 5.6% per jaar).

Hoge groei-inkomsten: De omzet van CDX ( 54.8% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen CDX zal naar verwachting over 3 jaar laag zijn ( 1 %).

CardieX Toekomstige groei

Future criteriumcontroles 5/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

New minor risk - Share price stability

CardieX Limited, Annual General Meeting, Nov 29, 2024

Full year 2024 earnings released: AU$0.034 loss per share (vs AU$0.14 loss in FY 2023)

CardieX (ASX:CDX) Is Carrying A Fair Bit Of Debt

Full year 2024 earnings released: AU$0.038 loss per share (vs AU$0.14 loss in FY 2023)

New major risk - Market cap size

Less than half of directors are independent

CardieX Limited Appoints Charlie Taylor as an Independent Non-Executive Director, Effective 1 March 2024

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 4 million.

CardieX Limited has filed a Follow-on Equity Offering in the amount of AUD 7.62 million.

CardieX Limited, Annual General Meeting, Nov 30, 2023

CardieX Limited Announces Resignation of Lesa Musatto as Independent Non-Executive Director

Full year 2023 earnings released: AU$0.15 loss per share (vs AU$0.12 loss in FY 2022)

New minor risk - Financial data availability

CardieX Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

CardieX Limited announced that it expects to receive AUD 2.3 million in funding

First half 2023 earnings released: AU$0.072 loss per share (vs AU$0.053 loss in 1H 2022)

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.044413 million.

CardieX Limited Appoints Reid Yeoman as the Group's New Us Based Chief Financial Officer

CardieX Limited (ASX:CDX) acquired All the Assets of Blumio, Inc.

Less than half of directors are independent

CardieX Limited, Annual General Meeting, Nov 30, 2022

CardieX Limited Auditor Raises 'Going Concern' Doubt

Full year 2022 earnings released: AU$0.12 loss per share (vs AU$0.059 loss in FY 2021)

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million.

Full year 2022 earnings released: AU$0.11 loss per share (vs AU$0.064 loss in FY 2021)

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.330001 million.

CardieX Limited Announces FDA 510(K) Submission for Conneqt Pulse Dual Blood Pressure and Arterial Health Monitor

FDA Update for CONNEQT Companion App of Cardiex Limited

CardieX Limited Announces Appointment of Lesa Musatto as an Independent, Non-Executive Director

Less than half of directors are independent

CardieX Submits FDA Application for its CONNEQT App

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Global Health Technology Company CardieX and Mobvoi Launch a Revolutionary Heart Health Monitoring Smartwatch for Consumers

Full year 2021 earnings released: AU$0.006 loss per share (vs AU$0.005 loss in FY 2020)

Full year 2021 earnings released: AU$0.006 loss per share (vs AU$0.005 loss in FY 2020)

CardieX Launches CONNEQT™

What Can We Learn About CardieX's (ASX:CDX) CEO Compensation?

Shareholders Are Thrilled That The CardieX (ASX:CDX) Share Price Increased 169%

CardieX Limited Announces New Devices on Track for Launch in 2021

CardieX Limited Announces Executive Appointments

Have Insiders Been Buying CardieX Limited (ASX:CDX) Shares?

CardieX Limited, Annual General Meeting, Dec 11, 2020

CardieX Limited Limited Announces Commercial Partnership Agreement with Mobvoi for New Health Smartwatch

Full year earnings released - AU$0.0046 loss per share

Full year earnings released - AU$0.0046 loss per share

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven